公开(公告)号：US20150368251A1

公开(公告)日：2015-12-24

申请号：US14765906

申请日：2014-02-04

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao WANG ,  Zhongxing ZHANG ,  Eric GILLIS ,  Paul Michael SCOLA

IPC: C07D487/08 ,  A61K31/53

CPC classification number: C07D487/08 ,  A61K31/53 ,  C07D498/08

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract translation: 除了使用这些化合物的组合物和方法之外，还列举了式I化合物，包括其药学上可接受的盐。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。

公开(公告)号：US20230063238A1

公开(公告)日：2023-03-02

申请号：US17791023

申请日：2020-11-19

Applicant: Bristol-Myers Squibb Company

Inventor： Tao WANG ,  Paul Michael SCOLA ,  Zhongxing ZHANG

IPC: C07D513/14 ,  A61P35/00

Abstract: In accordance with the present disclosure, macrocyclic compounds of formula (I) have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.

公开(公告)号：US20230022400A1

公开(公告)日：2023-01-26

申请号：US17777917

申请日：2020-11-19

Applicant: Bristol-Myers Squibb Company

Inventor： Tao WANG ,  Paul Michael SCOLA ,  Zhongxing ZHANG

IPC: C07K7/56

Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.

公开(公告)号：US20210053972A1

公开(公告)日：2021-02-25

申请号：US16963557

申请日：2019-01-23

Applicant: Bristol-Myers Squibb Company

Inventor： Kap-Sun YEUNG ,  Juliang ZHU ,  Paul Michael SCOLA

IPC: C07D471/10 ,  A61K31/438 ,  C07K14/705

Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

公开(公告)号：US20160024111A1

公开(公告)日：2016-01-28

申请号：US14771827

申请日：2014-03-05

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao WANG ,  Zhiwei YIN ,  Paul Michael SCOLA

IPC: C07D498/08 ,  A61K45/06 ,  A61K31/53

CPC classification number: C07D498/08 ,  A61K31/53 ,  A61K45/06

Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

公开(公告)号：US20150368267A1

公开(公告)日：2015-12-24

申请号：US14765910

申请日：2014-02-04

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Tao WANG ,  Zhongxing ZHANG ,  Zhiwei YIN ,  Li-Qiang SUN ,  Eric MULL ,  Qian ZHAO ,  Paul Michael SCOLA

IPC: C07D498/22 ,  A61K31/53 ,  C07D498/20 ,  A61K31/551 ,  C07D498/08 ,  A61K45/06 ,  C07D498/18

CPC classification number: C07D498/22 ,  A61K31/53 ,  A61K31/551 ,  A61K45/06 ,  C07D498/08 ,  C07D498/18 ,  C07D498/20

Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.

Abstract translation: 除了使用这些化合物的组合物和方法之外，还列举了式I化合物，包括其药学上可接受的盐。 该化合物具有抗丙型肝炎病毒（HCV）的活性，可用于治疗HCV感染者。